Fevipiprant (INN; code name QAW039) is a drug being developed by Novartis which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2)
| Product Name: | Fevipiprant |
| Synonyms: | Fevipiprant;Fevipipran;NVP-QAW039;Fevipiprant(NVP-QAW039);QAW039;Fevipiprant (QAW039);2-Methyl-1-[[4-(methylsulfonyl)-2-(trifluoromethyl)phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-3-acetic acid |
| CAS: | 872365-14-5 |
| MF: | C19H17F3N2O4S |